SPOTLIGHT: The GLP-1 Reckoning
May 2026
GLP-1s caught most employers off guard. Many added coverage, utilization exploded, and the bills came in well above anything they had budgeted for. Two years later, employers who have continued to cover GLP-1s are watching costs climb faster ...
Brought to you by the
GLP-1 coverage for weight loss has grown fast among large employers, but it is nowhere close to standard, and the momentum may already be reversing.
34% of non-elderly people with employer-sponsored insurance, roughly 36 million people, have a BMI that would qualify them for a GLP-1.
One in five firms with 200 or more workers covers GLP-1s for weight loss, including 43% of firms with 5,000 or more workers, up from 28% the year before.
Of employers currently covering GLP-1s for weight management, only 72% expect to continue in 2027, and 10% say they likely will not. Employers without coverage are unlikely to add it.
Several major health plans have dropped weight loss coverage entirely, including Blue Cross Blue Shield of Massachusetts, Blue Cross Blue Shield of Michigan, and Harvard Pilgrim Health Care.
Read more via Peterson-KFF Health System Tracker, HR Dive, Healthcare Dive, Marsh via Plan Sponsor, MedCity News, PHTI, SHRM
The drugs work. They are also expensive, the utilization is hard to predict, and costs are landing well above what most employers budgeted.
Nearly 8 in 10 employers say GLP-1s are driving up their healthcare spend. GLP-1s now make up roughly 20% of total prescription drug costs and drove about half of all drug spending growth in 2024.
Total GLP-1 spend increased around 50% in 2025, and prescription drug costs overall are rising 13% to 15% annually. Brand-name injectable GLP-1s typically cost between $1,000 and $1,500 a month, with employers covering 70% to 100% of that cost.
Among the largest employers, 66% say GLP-1 coverage had a significant impact on prescription drug spending, and 59% say utilization came in higher than expected.
Companies cannot ignore the reality that GLP-1s have significant implications for health care budgets — and overall affordability."
Read more via Peterson-KFF, HR Dive, SHRM, Fierce Healthcare, Plan Sponsor, PHTI
Employers are seeking tighter eligibility rules, mandatory lifestyle programs, and in some cases, cutting coverage altogether.
Most employers covering GLP-1s have added guardrails, including clinical eligibility checks, prescriber limits, and requirements to participate in a weight management program. The share requiring lifestyle program participation jumped from 10% to 34% in a single year.
Some employers have dropped weight loss coverage entirely and restricted GLP-1s to employees with a confirmed diabetes diagnosis, though several report that even diabetes-only coverage still lands GLP-1s in their top pharmacy spend.
Self-insured employers face a trap: tightening eligibility or blocking non-network prescriptions can trigger loss of PBM rebates, wiping out much of the financial benefit of restricting coverage.
GLP-1s are not short-term therapies, so employers have to decide how long they're willing to fund treatment and what success looks like."
Read more via Peterson-KFF , HR Dive, Healthcare Dive, PHTI, Wex, SHRM, Managed Healthcare Executive
Most employees who start GLP-1s do not stay on them long enough to generate the outcomes employers are paying for. And when they stop, the weight comes back fast.
Real-world claims data show fewer than 70% of commercially insured individuals without diabetes stay on GLP-1 therapy after one year. Only 30% are still on them after two years, compared to 87% completion in clinical trials.
The two most common reasons for stopping are cost and side effects, primarily nausea, vomiting, and gastrointestinal distress. A study of 77,310 first-time semaglutide users in Denmark found more than half stopped within one year, with 42% stopping within nine months.
When patients stop, they typically regain two-thirds of their prior weight loss within a year. Adherence is the primary driver of both better health outcomes and reduced costs.
Paying for a GLP-1 and having someone stop taking it is like flushing money down the toilet.”
Read more via PHTI, AJMC, Managed Healthcare Executive, HR Dive
The clinical case for these drugs is strong. The return is real for sustained users, but it takes longer to materialize than most workers spend at any one employer.
More than half of employers covering GLP-1s expect significant clinical benefits. Few have seen evidence of lower obesity rates or fewer bariatric surgeries in their claims yet.
Aon's analysis of more than 192,000 GLP-1 users found those using the drugs for weight loss had 3% to 7% lower medical costs within 18 months. Sustained users experienced a 44% reduction in cardiac events and lower rates of a range of serious conditions.
For women, female GLP-1 users had a 47% reduction in hospitalizations for major cardiovascular events, about 50% lower incidence of ovarian cancer, and 14% lower incidence of breast cancer.
Drug costs outpace savings in other medical spending over the typical 3-to-4-year period most workers stay on an employer plan, meaning most of the long-term return lands somewhere else.
Read more via SHRM, Managed Healthcare Executive, Peterson-KFF Health System Tracker, Healthcare Dive, PHTI
The pressure on employer pharmacy budgets is not close to peaking. Pills, new FDA indications, and Medicare expansion are all arriving at the same time.
The oral version of Wegovy was approved by the FDA late in 2025. Foundayo, an oral GLP-1 from Eli Lilly, was approved in April 2026. 87% of employers expect oral formulations to drive higher demand. Only 9% expect prices to drop.
Pills are expected to bring in employees who declined weekly injections, expanding the treatment-seeking population. Lower manufacturing costs may reduce unit prices, but higher utilization is expected to more than offset any savings.
While the innovation improves access, it also raises the risk that total GLP-1 spend could climb rapidly unless employers are actively managing who can access these therapies and how they're used over time."
Nearly 58 million commercially insured adults currently qualify for GLP-1s. Potential new FDA indications for cardiovascular disease, chronic kidney disease, and addiction would expand that pool further. Medicare will cover obesity drugs for the first time later in 2026, under deals between Lilly, Novo Nordisk, and the Trump administration.
At a time when employers are already facing cost pressures from rising utilization in the weight-loss drug category, the new GLP-1 pills could accelerate that pressure when most are trying to reduce costs."
Read more via SHRM, Healthcare Dive, CNBC, PHTI, Wex, Peterson-KFF Health System Tracker
Employers have broad discretion on GLP-1 coverage, but decisions that cover some conditions and not others carry legal risk worth understanding before making changes.
No federal law requires employers to cover GLP-1s for weight loss or diabetes. Fully insured plans must comply with applicable state mandates.
Employers who cover GLP-1s for diabetes but exclude obesity coverage could potentially face scrutiny under the ADA, the ACA, HIPAA nondiscrimination rules, or the Mental Health Parity and Addiction Equity Act. District courts have ruled inconsistently, and some state and local laws include weight as a protected class.
North Dakota is the only state currently requiring GLP-1 coverage for weight-related treatment, applying to individual and small group ACA plans beginning in 2025. New Hampshire has introduced legislation that would extend a similar requirement to certain fully insured commercial plans.
Read more via Fisher Phillips
Employers looking for alternatives to traditional GLP-1 coverage have more options than they did a year ago, ranging from a new manufacturer-backed pricing platform to tax-advantaged accounts and point solutions.
Launched in March 2026, Employer Connect lets employers pay a flat, rebate-free net price of $449 per month for a multi-dose form of Zepbound, with more than 15 third-party administrators to choose from, including GoodRx, Cost Plus Drug Co., Teladoc Health, eMed, Form Health, and Waltz Health. All sourcing on Employer Connect comes from Lilly's own spokespeople.
HSAs and FSAs allow employees to use pre-tax dollars for eligible prescription medications, including GLP-1s, though the financial burden largely shifts to the employee. A defined HRA is a more structured option, letting employers set a spending cap and convert a variable cost into a predictable one.
Point solutions offer another route. eMed offers healthcare organizations GLP-1 access for $25 per covered life per month, with eligible employees paying $99 per month.
PHTI recommends employers pair GLP-1 access with clinically driven eligibility criteria, mandatory lifestyle program participation, structured support for employees who stop therapy, and outcome-based vendor contracts that reward adherence rather than prescription volume.
Read more via CNBC, Peterson-KFF Health System Tracker, Fisher Phillips, Wex, HR Brew, PHTI
